Axonyx, Inc.
Axonyx completes multiple-dose phase I study of Posiphen
Published in Aging and Elder Health Week, June 18th, 2006
This double-blind, placebo-controlled multiple ascending-dose safety and pharmacokinetic study of Posiphen in healthy volunteers sought to establish well tolerated doses.
The initial review of the clinical adverse event data appears to be generally consistent with the results of the earlier single ascending dose phase I study that suggested that the mean Posiphen blood levels associated with well tolerated doses in humans are higher than those associated with potentially beneficial effects...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging and Elder Health Week
More Articles from Aging and Elder Health Week
- Amarin Corp. plc
Amarin acquires Parkinson disease drug candidate - Breast Cancer
Weight gain in women increases risk of all types of breast cancer - Campus Biomedico University, Rome
Researchers from Italy and France report recent findings in lung cancer - Dementia
Characteristics of caregivers may increase symptoms in dementia patients - Erasmus Medical Center, Rotterdam
Researchers from Erasmus Medical Center, Rotterdam publish new findings - Finance
Intrepid's Rx Fulfillment sees significant increase in long-term care prescription sales - More from this issue of Aging and Elder Health Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
